MYGN.NASDAQMyriad Genetics INC
DEF 14A: Myriad Genetics Reports Strong 2023 Results, Focuses on Strategic Growth
Sentiment:
Definitive Proxy Statement
Myriad Genetics highlights 11% revenue growth in 2023 and strategic advancements in molecular diagnostics and precision medicine.
Capital raiseMyriad Genetics raised $118 million in a successful equity offering in November 2023.The funds are intended to allow management to focus more on operational execution and achievement of long-term strategic goals.
Summary
- Myriad Genetics reported a strong 2023, marked by an 11% increase in total revenue, reaching $753.2 million.
- This growth was primarily driven by a 30% increase in Prenatal revenue, along with growth in Prolaris (21%), GeneSight (9%), and Hereditary Cancer (7%) revenues.
- The company achieved positive adjusted earnings per share and adjusted operating cash flow in the fourth quarter of 2023.
- A successful equity offering raised $118 million, strengthening the company's financial position.
- The Net Promoter Score (NPS) improved to 69.8, reflecting increased satisfaction among healthcare providers.
- Voluntary employee turnover reached a multi-year low at approximately 9% in the fourth quarter of 2023.
- The company acquired Precise Tumor and Precise Liquid tests from Intermountain Precision Genomics (IPG) to expand oncology testing options.
- Myriad plans to launch Foresight Universal Plus, FirstGene, Precise Liquid comprehensive genomic panel, and Precise MRD for research use.
- The company completed construction of new research and innovation centers in South San Francisco and Salt Lake City.
- Electronic medical record (EMR) integrations were completed at 1,200 locations in 2023, with plans to add over 1,900 more in 2024.
Sentiment
Score: 7
Explanation: The document presents a generally positive outlook, highlighting revenue growth, strategic acquisitions, and improved operational efficiency. However, the presence of GAAP losses and a competitive market temper the overall sentiment.
Positives
- Strong revenue growth driven by key product lines.
- Improved healthcare provider satisfaction, as indicated by the Net Promoter Score.
- Reduced employee turnover, suggesting a positive work environment.
- Successful capital raise to support strategic goals.
- Strategic acquisition to expand oncology testing options.
- Robust product pipeline with planned launches of new tests.
- Investments in new facilities to enable high-volume growth at lower costs.
- Expansion of digital technology to improve customer experience.
Negatives
- GAAP operating loss was $(257.4) million.
- GAAP loss per share was $(3.18).
- The company's engagement score decreased from 61 in 2022 to 56 in 2023.
Risks
- The market for precision medicine is highly fragmented with less than 20% market share concentrated among the top players.
- The company faces risks described in its annual report on Form 10-K for the year ended December 31, 2023.
Future Outlook
Myriad Genetics is increasingly optimistic about 2024 performance, expecting continued growth in existing products and the launch of new products.
Management Comments
- 2023 was another exciting year of progress for Myriad Genetics.
- With our mission at the forefront of every action we take, we delivered strong results and we continue to execute on our long-term strategic growth plan.
- We are focused on continually addressing our customers needs, coordinating across the company to ensure that we are all working towards delivering a superior customer experience that is differentiated from our competitors.
- With this strong performance and new opportunities for gaining market share, we are increasingly optimistic about 2024 performance.
- Our modernized laboratory facilities and robust commercial engine are examples of where our investments in automation and advanced technology are yielding improved workflows, faster turnaround times and reduced operating costs.
- With increasing expansion of use cases for genetic testing and the adoption of precision medicine, we believe we are poised for both organic growth and market share gains in a dynamic industry.
Industry Context
The document notes that the precision medicine market is highly fragmented, with less than 20% market share concentrated among the top players, presenting a significant opportunity for Myriad Genetics to gain market share.
Comparison to Industry Standards
- The document compares Myriad's stock performance to the Nasdaq Composite Index (IXIC) and the Nasdaq Health Care Index (IXHC).
- Over the past five years, Myriad experienced a (8.0)% annual stockholder return versus a 17.7% return for the IXIC and a 6.0% return for the IXHC.
- Since the start of fiscal year 2021, Myriad has experienced a (1.1)% annual stockholder return versus a 5.2% return for the IXIC and a (6.5)% return for the IXHC.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Operating Officer | Nicole Lambert | Sam Raha | 2023-12-11 | Resignation of previous COO |
| Chief Financial Officer | R. Bryan Riggsbee | Scott Leffler | 2024-01-29 | Resignation of previous CFO |
| Chief People Officer | NA | Shereen Solaiman | 2023-03-01 | New hire |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Clawback Policy | The Board adopted a new Clawback Policy that complies with the rules promulgated by the U.S. Securities and Exchange Commission and the Nasdaq Stock Market LLC. | 2023 | Recoupment of certain executive compensation in the event of an accounting restatement. |
| Amendment to Restated Certificate of Incorporation | Amendments to our Restated Certificate of Incorporation, as amended, to (1) limit the personal liability of certain of our senior officers as permitted by recent amendments to Delaware law and (2) add a federal forum selection clause for claims under the Securities Act of 1933, as amended. | 2023-06-01 | Limit the personal liability of certain of our senior officers and add a federal forum selection clause for claims under the Securities Act of 1933, as amended. |
Stakeholder Impact
- Shareholders: The company's performance and strategic initiatives aim to increase long-term shareholder value.
- Employees: The company is committed to creating a positive work environment with competitive compensation and benefits.
- Customers: The company focuses on delivering a superior customer experience through high-quality tests and digital technology.
- Patients: The company's mission is to advance the health and well-being of patients through molecular diagnostic tests.
Next Steps
- Continue to build on the pillars of long-term revenue growth and adjusted profitability.
- Continue working with determination to advance our mission, achieve our ambitious goals and exceed your expectations.
- Continue to focus on accelerating growth profitably.
- Continue to focus on ongoing development and commercialization of differentiated molecular diagnostic tests.
- Continue to leverage technology and scale in our laboratory and and commercial operations to make our genetic tests more accessible and affordable.
Key Dates
| Date | Description |
|---|---|
| 2009-09 | S. Louise Phanstiel joined the Board of Directors |
| 2010-06 | Heiner Dreismann, Ph.D., joined as a director of Myriad |
| 2014-10 | R. Bryan Riggsbee was appointed Chief Financial Officer |
| 2017-08-01 | Mark Verratti was appointed to the position of President of Myriad Neuroscience |
| 2019-09 | Lee Newcomer, M.D., was appointed as a member of the Board |
| 2019-09 | Colleen F. Reitan was appointed as a member of the Board |
| 2020-02-06 | R. Bryan Riggsbee was appointed interim President and Chief Executive Officer |
| 2020-05 | Daniel K. Spiegelman has been a director of the Company since May 2020 |
| 2020-07 | Daniel M. Skovronsky, M.D., Ph.D., joined the Company as a Director in July 2020 |
| 2020-08-13 | Paul J. Diaz was appointed as the President and Chief Executive Officer of Myriad Genetics, Inc. |
| 2020-09 | Rashmi Kumar has been a director of Myriad since September 2020 |
| 2021-01-01 | Maggie Ancona joined Myriad in January 2021 |
| 2021-01-01 | Effective January 1, 2021, the Company transitioned from a fiscal year ending June 30 to December 31 |
| 2021-02 | Kevin R. Haas was appointed Chief Technology Officer in February 2021 |
| 2022-01-01 | Nicole Lambert was appointed to serve as our Chief Operating Officer, effective January 1, 2022 |
| 2022-04-14 | Mark Verratti was promoted to Chief Commercial Officer on April 14, 2022 |
| 2022-04-14 | Dale Muzzey was appointed Chief Scientific Officer of Myriad in April 2022 |
| 2022-10-31 | Paul M. Bisaro was appointed as a director of Myriad on October 31, 2022 |
| 2023-03-01 | Shereen Solaiman, Chief People Officer, joined Myriad Genetics in March 2023 |
| 2023-06-01 | Our stockholders approved the compensation of our NEOs with 96% of the votes cast in favor of our Say-on-Pay resolution at our 2023 Annual Meeting of Stockholders |
| 2023-09-21 | On September 21, 2023, our Board adopted a new Clawback Policy |
| 2023-10-04 | On October 4, 2023, Ms. Lambert and the Company mutually reached an agreement that Ms. Lambert would resign from her position as Chief Operating Officer, effective October 31, 2023 |
| 2023-12-11 | Sam S. Raha became Chief Operating Officer of Myriad in December 2023 |
| 2023-12-15 | On December 15, 2023, Mr. Riggsbee and the Company mutually reached an agreement that Mr. Riggsbee would resign from his position as Chief Financial Officer, effective January 29, 2024 |
| 2024-01-29 | Scott J. Leffler became Chief Financial Officer of Myriad on January 29, 2024 |
| 2024-02 | In February 2024, we acquired select assets from Intermountain Precision Genomics' laboratory business |
| 2024-06-06 | Date of the 2024 Annual Meeting of Stockholders |
Keywords
genetics, precision medicine, molecular diagnostics, oncology, prenatal, GeneSight, Myriad Genetics, revenue growth, equity offering, NPS, employee turnover
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.